$0.76
-0.13 (-14.90%)
Open$0.84
Previous Close$0.89
Day High$0.84
Day Low$0.71
52W High$3.39
52W Low$0.16
Volume—
Avg Volume14.93M
Market Cap163.15M
P/E Ratio—
EPS$-1.26
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+4,498.1% upside
Current
$0.76
$0.76
Target
$34.78
$34.78
$27.07
$34.78 avg
$51.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 8.76M | 11.36M | 5.83M |
| Net Income | -386,964,376 | -451,885,219 | -1,267,217 |
| Profit Margin | -4,416.2% | -4,195.4% | -21.7% |
| EBITDA | -414,983,703 | -511,527,855 | -1,820,131 |
| Free Cash Flow | — | — | -1,133,887 |
| Rev Growth | -22.9% | -22.9% | +8.5% |
| Debt/Equity | 1.25 | 1.25 | 0.66 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |